Delcath Granted Orphan-Drug Status for Doxorubicin

Delcath Systems, Inc. announced that the FDA granted Delcath’s request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma, also known as primary liver cancer.
StreetInsider.com